DexCom, Inc. (NASDAQ:DXCM) CEO Kevin R. Sayer Sells 45,607 Shares

DexCom, Inc. (NASDAQ:DXCM – Get Rating) CEO Kevin R. Sayer sold 45,607 shares of the company’s stock in a transaction on Friday, January 20th. The shares were sold at an average price of $105.75, for a total transaction of $4,822,940.25. Following the sale, the chief executive officer now directly owns 426,645 shares in the company, valued at approximately $45,117,708.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

DexCom Trading Down 0.3 %

Shares of NASDAQ DXCM traded down $0.37 during mid-day trading on Tuesday, reaching $106.03. The company had a trading volume of 1,685,571 shares, compared to its average volume of 2,616,071. The company has a current ratio of 3.77, a quick ratio of 3.43 and a debt-to-equity ratio of 1.08. DexCom, Inc. has a 52 week low of $66.89 and a 52 week high of $134.76. The business’s 50-day moving average is $113.06 and its 200-day moving average is $99.19. The stock has a market cap of $40.95 billion, a price-to-earnings ratio of 196.13, a price-to-earnings-growth ratio of 2.95 and a beta of 1.14.

DexCom (NASDAQ:DXCM – Get Rating) last issued its earnings results on Thursday, October 27th. The medical device company reported $0.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.24 by $0.04. DexCom had a net margin of 8.24% and a return on equity of 13.27%. The company had revenue of $769.60 million for the quarter, compared to analysts’ expectations of $752.67 million. Equities analysts expect that DexCom, Inc. will post 0.79 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Oak Ridge Investments LLC grew its holdings in DexCom by 309.7% during the 4th quarter. Oak Ridge Investments LLC now owns 40,855 shares of the medical device company’s stock worth $4,626,000 after acquiring an additional 30,883 shares in the last quarter. Covenant Asset Management LLC grew its holdings in DexCom by 2.0% during the 4th quarter. Covenant Asset Management LLC now owns 21,300 shares of the medical device company’s stock worth $2,412,000 after acquiring an additional 420 shares in the last quarter. First Citizens Bank & Trust Co. bought a new stake in shares of DexCom in the 4th quarter valued at about $264,000. MUFG Securities EMEA plc bought a new stake in shares of DexCom in the 4th quarter valued at about $4,983,000. Finally, Empirical Finance LLC boosted its holdings in shares of DexCom by 9.9% in the 4th quarter. Empirical Finance LLC now owns 9,459 shares of the medical device company’s stock valued at $1,071,000 after buying an additional 851 shares in the last quarter. 94.01% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the stock. Cowen increased their target price on shares of DexCom from $85.00 to $114.00 in a research note on Friday, October 28th. Piper Sandler increased their target price on shares of DexCom to $130.00 in a research note on Tuesday, November 1st. Wells Fargo & Company increased their target price on shares of DexCom from $102.00 to $128.00 and gave the company an “overweight” rating in a research note on Friday, October 28th. Morgan Stanley increased their target price on shares of DexCom from $117.00 to $131.00 and gave the company an “equal weight” rating in a research note on Friday, January 6th. Finally, Stifel Nicolaus increased their target price on shares of DexCom from $120.00 to $130.00 in a research note on Tuesday, December 20th. Three research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $122.00.

About DexCom

(Get Rating)

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system.